Identifying Molecular Drivers of Cellular Plasticity in Pancreatic Cancer
识别胰腺癌细胞可塑性的分子驱动因素
基本信息
- 批准号:10252885
- 负责人:
- 金额:$ 36.94万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2020
- 资助国家:美国
- 起止时间:2020-09-03 至 2025-05-31
- 项目状态:未结题
- 来源:
- 关键词:AddressAutomobile DrivingBiologyCancer EtiologyCell LineCellsCessation of lifeClassificationClinicCoculture TechniquesDiseaseEffectivenessEpithelial CellsErinaceidaeGLI2 geneGene Expression ProfilingGeneticGenetic TranscriptionGoalsHumanKRAS2 geneLigandsMaintenanceMalignant neoplasm of pancreasMediatingMetastatic toModelingMolecularMusNeoplasm MetastasisOutcomePancreatic Ductal AdenocarcinomaPathway interactionsPatientsPharmacologyPhenotypePrimary NeoplasmProcessPrognosisRelapseResectedResistanceRoleSpecimenUp-RegulationVariantWestern WorldWorkautocrinechemotherapyclinically relevantcombatconditioningdisorder subtypeeffective therapygain of functionhuman modelin vivomutantneoplastic cellosteopontinoverexpressionpancreatic ductal adenocarcinoma cellparacrineprogramsresistance mechanismresponsetargeted treatmenttranscription factortumortumor growthtumor progressiontumorigenic
项目摘要
PROJECT SUMMARY
Pancreatic ductal adenocarcinoma (PDA) is a highly aggressive disease that is projected to become the second
leading cause of cancer deaths in the Western world by 2030. Recently, studies utilizing transcriptional profiling
from resected PDA specimens have identified two molecularly distinct subtypes termed Classical and Basal.
These subtypes correlate with overall patient survival, with the Basal subtype predictive of higher rates of
metastasis, poor response to therapy and the worst outcomes. While this classification represents an important
breakthrough for identifying patients with the most aggressive variant of PDA, the underlying circuits that drive
key features of this variant are unknown. Without a clear understanding of this biology, our ability to effectively
treat patients with the deadliest form of PDA is compromised. Thus, a major goal in the field is to identify drivers
of the Classical and Basal subtypes of PDA in order to 1) effectively target Basal PDA or 2) promote conversion
to a less aggressive variant (Classical) that may respond more effectively to therapy.
Towards this goal, we have discovered that the Hedgehog pathway transcription factor, GLI2, functions
in a non-canonical ligand independent manner as a critical regulator of the most aggressive Basal subtype of
PDA (Adams et al eLife, 2019; PMC6538376). The key findings in support of this model are, (1) GLI2 expression
is elevated in Basal PDA cell lines and patient tumors and predicts shorter survival in patients, (2) GLI2
suppression leads to loss of Basal identity and inhibits tumor growth while ectopic GLI2 expression in Classical
PDA cells causes a switch to the Basal state (3). Our findings underscore a previously unrecognized level of
plasticity in PDA cells and highlight an entirely new role for GLI2 in driving Basal identity in this disease. Building
on this work, we hypothesize that suppression of GLI2 represents a unique vulnerability in Basal PDA to
combat KRAS* resistance and tumor progression. Thus, we propose 2 specific aims that will 1) define the
non-canonical transcriptional circuits regulated by GLI2 in a cell-autonomous manner to mediate resistance to
KRAS* pathway suppression and 2) determine how GLI2-dependent secreted factors condition surrounding cells
to promote primary and metastatic tumor growth. These studies will determine the cellular circuits that control
Basal identity, define their role in the context of KRAS* resistance, tumor relapse and metastasis and lay the
groundwork for increasing the effectiveness of KRAS-targeted therapies that have entered the clinic.
项目摘要
胰腺导管腺癌(PDA)是一种高度侵袭性的疾病,预计将成为第二大
到2030年,癌症将成为西方世界的主要死因。最近,利用转录谱的研究
从切除的PDA标本中鉴定出两种分子上不同的亚型,称为经典型和基底型。
这些亚型与患者的总体生存率相关,其中基础亚型预测较高的生存率。
转移,对治疗的反应差和最差的结果。虽然这种分类代表了一个重要的
这是一项突破,用于识别患有最具侵略性的PDA变体的患者,
该变种的主要特征尚不清楚。如果没有对这种生物学的清晰理解,我们有效地
治疗最致命的动脉导管未闭患者的能力受到了影响。因此,该领域的一个主要目标是确定驱动因素
为了1)有效靶向基础PDA或2)促进转化,
一种攻击性较低的变体(经典型),可能对治疗反应更有效。
为了实现这一目标,我们发现Hedgehog途径转录因子GLI 2,
以非典型配体独立的方式作为最具侵袭性的基底亚型的关键调节剂,
PDA(亚当斯等人eLife,2019; PMC 6538376)。支持这一模型的关键发现是,(1)GLI 2表达
在基底PDA细胞系和患者肿瘤中升高,并预测患者的生存期较短,(2)GLI 2
抑制导致基底细胞特性丧失并抑制肿瘤生长,而在经典肿瘤中异位GLI 2表达
PDA细胞导致转换为基础状态(3)。我们的研究结果强调了以前未被认识到的
这一发现揭示了PDA细胞的可塑性,并突出了GLI 2在这种疾病中驱动基底细胞身份的全新作用。建筑
在这项工作中,我们假设GLI 2的抑制代表了基底动脉粥样硬化的独特脆弱性,
对抗KRAS* 抗性和肿瘤进展。因此,我们提出了2个具体目标,1)定义
GLI 2以细胞自主方式调节的非经典转录回路介导对
KRAS* 通路抑制和2)确定GLI 2依赖性分泌因子如何调节周围细胞
以促进原发性和转移性肿瘤生长。这些研究将确定细胞回路控制
基础身份,定义其在KRAS* 耐药、肿瘤复发和转移背景下的作用,并奠定其基础。
为提高已进入临床的KRAS靶向治疗的有效性奠定了基础。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Rushika Miriam Perera其他文献
Rushika Miriam Perera的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Rushika Miriam Perera', 18)}}的其他基金
Targeting the autophagy-lysosome system to block pancreatic cancer
靶向自噬溶酶体系统来阻止胰腺癌
- 批准号:
10212065 - 财政年份:2021
- 资助金额:
$ 36.94万 - 项目类别:
Targeting the autophagy-lysosome system to block pancreatic cancer
靶向自噬-溶酶体系统来阻止胰腺癌
- 批准号:
10358483 - 财政年份:2021
- 资助金额:
$ 36.94万 - 项目类别:
Targeting the autophagy-lysosome system to block pancreatic cancer
靶向自噬-溶酶体系统来阻止胰腺癌
- 批准号:
10590682 - 财政年份:2021
- 资助金额:
$ 36.94万 - 项目类别:
Dissecting new mechanisms of lysosome quality control in health and disease
剖析健康和疾病中溶酶体质量控制的新机制
- 批准号:
10594038 - 财政年份:2021
- 资助金额:
$ 36.94万 - 项目类别:
Dissecting new mechanisms of lysosome quality control in health and disease
剖析健康和疾病中溶酶体质量控制的新机制
- 批准号:
10186267 - 财政年份:2021
- 资助金额:
$ 36.94万 - 项目类别:
Dissecting new mechanisms of lysosome quality control in health and disease
剖析健康和疾病中溶酶体质量控制的新机制
- 批准号:
10370440 - 财政年份:2021
- 资助金额:
$ 36.94万 - 项目类别:
Identifying Molecular Drivers of Cellular Plasticity in Pancreatic Cancer
识别胰腺癌细胞可塑性的分子驱动因素
- 批准号:
10404053 - 财政年份:2020
- 资助金额:
$ 36.94万 - 项目类别:
Identifying Molecular Drivers of Cellular Plasticity in Pancreatic Cancer
识别胰腺癌细胞可塑性的分子驱动因素
- 批准号:
10626914 - 财政年份:2020
- 资助金额:
$ 36.94万 - 项目类别:
Identifying Molecular Drivers of Cellular Plasticity in Pancreatic Cancer
识别胰腺癌细胞可塑性的分子驱动因素
- 批准号:
9974205 - 财政年份:2020
- 资助金额:
$ 36.94万 - 项目类别:
相似海外基金
Establishment of a method for evaluating automobile driving ability focusing on frontal lobe functions and its application to accident prediction
以额叶功能为中心的汽车驾驶能力评价方法的建立及其在事故预测中的应用
- 批准号:
20K07947 - 财政年份:2020
- 资助金额:
$ 36.94万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Evaluation of the Effectiveness of Multi-Professional Collaborative Assessment of Cognitive Function and Automobile Driving Skills and Comprehensive Support
认知功能与汽车驾驶技能多专业协同评估效果评价及综合支持
- 批准号:
17K19824 - 财政年份:2017
- 资助金额:
$ 36.94万 - 项目类别:
Grant-in-Aid for Challenging Research (Exploratory)
Development of Flexible Automobile Driving Interface for Disabled People
残疾人灵活汽车驾驶界面开发
- 批准号:
25330237 - 财政年份:2013
- 资助金额:
$ 36.94万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Automobile driving among older people with dementia: the effect of an intervention using a support manual for family caregivers
患有痴呆症的老年人的汽车驾驶:使用家庭护理人员支持手册进行干预的效果
- 批准号:
23591741 - 财政年份:2011
- 资助金额:
$ 36.94万 - 项目类别:
Grant-in-Aid for Scientific Research (C)